LAB enrolls first patients in phase 2a trial of LAB CGRP for asthma

By Lisa Kerner

Erie, Pa., April 18 - LAB International Inc. said it has enrolled the first of 12 patients in its LAB CGRP phase 2a trial, slated for completion in the third quarter of 2006.

LAB CGRP is a 37 amino acid natural neuropeptide produced in the lung in response to allergic stimuli.

The randomized, double blind, cross-over study is designed to investigate the protective efficacy of LAB CGRP on metacholine-induced bronchial hyper-responsiveness in adult patients with mild to moderate asthma. Additional objectives are to compare this efficacy to salbutamol and a placebo, and to evaluate the safety and tolerability of LAB CGRP in asthma patients.

"Patient enrollment for our first phase 2 trial marks yet another key milestone for the development of this drug," chief executive officer Halvor Jaeger said in a company news release.

"We are initiating this trial with confidence and excitement and look forward to demonstrating efficacy in asthma patients following compelling results previously obtained in preclinical studies. In these studies, LAB CGRP completely abolished airway hyper-responsiveness to metacholine and allergen challenges. Demonstrating the bronchodilatory, anti-inflammatory and broncho-protective properties in patients would represent a significant benefit over the usual combination asthma therapies."

LAB International is an integrated drug development company based in Laval, Quebec.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.